| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-06-01 | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute attacks of angioedema in pediatric patients with Hereditary Angioedema (HAE) | 2 | Pharming (The Netherlands) | Genetic diseases - Rare diseases |
| 2015-06-01 | miR-31-3p biomarker | metastatic colorectal cancer (mCRC) | Integragen (France) | Cancer - Oncology | |
| 2015-06-01 | BL-5010P | seborrheic keratosis |
1-2 | BioLineRx (Israel) | Dermatological diseases |
| 2015-06-01 | Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) | acute lymphoblastic leukemia | 3 | Erytech (France) | Cancer - Oncology |
| 2015-06-01 | BGB324 and BGB10C9 | pancreatic cancer | preclinical | BergenBio (Norway) | Cancer - Oncology |
| 2015-06-01 | PM1183 plus doxorubicin | small cell lung cancer | 1b | PharmaMar (Spain) | Cancer - Oncology |
| 2015-06-01 | AMV-564 | acute myeloid leukemia (AML) | preclinical | Amphivena Therapeutics (USA - CA) | Cancer - Oncology |
| 2015-06-01 | napabucasin (BBI608) | gastric cancer, gastroesophageal junction cancer | 3 | Boston Biomedical (USA - MA) | Cancer - Oncology |
| 2015-06-01 | NGR-hTNF | malignant pleural mesothelioma |
3 | MolMed (Italy) | Cancer - Oncology - Rare diseases |
| 2015-06-01 | CRLX101 - poly-CD-PEG-camptothecin | relapsed renal cell carcinoma |
1b-2 | Cerulean Pharma (USA - MA) | Cancer - Oncology |
| 2015-06-01 | sacituzumab govitecan - IMMU-132 | metastatic gastrointestinal cancers | Immunomedics (USA - NJ) | Cancer - Oncology | |
| 2015-05-31 | Kyprolis® (carfilzomib) | multiple myeloma | 1-2 | Amgen (USA - CA) Onyx Therapeutics (USA - CA) | Cancer - Oncology |
| 2015-05-31 | rociletinib (CO-1686) | non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations, as well as the dominant resistance mutation T790M |
2 | Clovis Oncology (USA - CO) | Cancer - Oncology |
| 2015-05-31 | evofosfamide (TH-302) | multiple myeloma | 1-2 | Threshold Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2015-05-30 | ONT-380 | Her2 positive metastatic breast cancer | 1b | Oncothyreon (USA - WA) | Cancer - Oncology |
| 2015-05-30 | Imbruvica® (ibrutinib) | relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | 3 | Pharmacyclics (USA - CA), now Abbvie (USA - IL) - Janssen-Cilag International, a J&J company (USA - NJ) | Cancer - Oncology |
| 2015-05-30 | Ibrance® (palbociclib) | HR+, HER2- metastatic breast cancer |
3 | Pfizer (USA - NY) | Cancer - Oncology |
| 2015-05-29 | Opdivo® (nivolumab) | hepatocellular carcinoma | 1-2 | BMS (USA - NY) | Cancer - Oncology |
| 2015-05-29 | dipraglurant (ADX48621) | dystonia | preclinical | Addex Therapeutics (Switzerland) | Neuromuscular diseases - Rare diseases - CNS diseases - Neurological diseases |
| 2015-05-29 | lexaptepid pegol (NOX-H94) | erythropoietin (EPO)-hyporesponsive anemia in dialysis patients | 2a | Noxxon Pharma (Germany) | Kidney diseases - Renal diseases |
